Researchers have created the largest atlas of post-zygotic mutations in healthy human tissue ever assembled, in a study published in the journal Science. Senior author Don Conrad, Ph.D., says, “If you’re talking about genetic changes being the basis of disease, there are a wide variety of technologies now that allow us to make changes to the genome. It may be possible to change those mutations we’ve acquired due to bad luck or bad habits.”

Paul Yang. M.D., Ph.D., discusses a Phase 1/2 clinical trial evaluating a potential gene therapy for a form of Leber congenital amaurosis, an inherited condition that causes severe vision impairment.

A press release noting Oregon is one of three states where proposed legislation would further protect gender-affirming care notes Christina Milano, M.D., testified before the Oregon Legislature about the importance of making gender-affirming health care accessible.

The Food and Drug Administration authorizes marketing for new treatment of osteoarthritis of the knee, based on nationwide clinical trials, including at OHSU. Dennis Crawford, M.D., says, “Quite frankly, there hasn’t been a substantial development for the treatment of this ubiquitous disease for more than 50 years."

News Medical Life Sciences covers new research led by OHSU finding that women vaccinated for COVID-19 have a slightly higher risk for a heavier period after vaccination.

In a Science News story about side effects, Alison Edelman, M.D., says that hormone-based birth control methods that “we have are already safe and effective” for the people cleared to use them.

The Statesman Journal reports that Gov. Tina Kotek is pushing legislation to shore up funding for behavioral health services, including $1.5 million to OHSU for the Behavioral Health Coordination Center. OHSU also previously received federal funding for the center.

KPTV covers experience of a patient left waiting and discharged prematurely from the emergency department at Hillsboro Medical Center last spring.

Skanska signs $111 million contract amendment with OHSU for the university's ongoing hospital expansion project.

The Food and Drug Administration authorizes marketing for new treatment of osteoarthritis of the knee, based on nationwide clinical trials, including at OHSU. Dennis Crawford, M.D., says, “Quite frankly, there hasn’t been a substantial development for the treatment of this ubiquitous disease for more than 50 years."